Development and Characterization of a Clobetasol Propionate Nanostructured Lipid Carrier-Based Gel for the Treatment of Plaque Psoriasis

Author(s): Ankita Dadwal, Neeraj Mishra, Raj K. Narang*

Journal Name: Current Molecular Pharmacology

Volume 14 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Psoriasis is an autoimmune disease of the skin with lapsing episodes of hyperkeratosis, irritation, and inflammation. Numerous traditional and novel drug delivery systems have been used for better penetration through psoriatic barrier cells and also for retention in the skin. As there is no effective remedy for better penetration, and retention is there because of the absence of an ideal carrier for effective and safe delivery of antipsoriatic drugs.

Objectives: The main objective of this project is to develop a Squalene integrated NLC based carbopol 940 gel to create a local drug depot in the skin for improved efficacy against psoriasis.

Methods: Homogenization method is used for the formulation of Nanostructured Lipid Carrier, which was characterized on the basis of size, entrapment efficiency, polydispersity index (PDI), viscosity, spreadability, DSC, zeta potential, % in vitro release, in vitro skin permeation and retention studies, physical storage stability studies. In vivo studies can use other alternative models for induction of psoriasis by severe redness, swelling macroscopically, and microvascular dilation edema lasting for 10 days. Furthermore, histopathology study was done to asses changes in the skin.

Conclusion: The optimized formulation of nanostructured lipid carrier-based gel has shown significant and sustained release of clobetasol propionate. Furthermore, this formulation has also shown retention in skin because of squalene as it is a sebum derived lipid, which shows an affinity towards the sebaceous gland.

Keywords: Clobetasol propionate, nanostructured lipid carrier, sebaceous gland, permeation, retention, gel, plaque psoriasis.

[1]
Afifi, T.; de Gannes, G.; Huang, C.; Zhou, Y. Topical therapies for psoriasis: Evidence-based review. Can. Fam. Physician, 2005, 51(4), 519-525.
[PMID: 15856971]
[2]
Lowes, M.A.; Suárez-Fariñas, M.; Krueger, J.G. Immunology of psoriasis. Annu. Rev. Immunol., 2014, 32, 227-255.
[http://dx.doi.org/10.1146/annurev-immunol-032713-120225] [PMID: 24655295]
[3]
Mazzotta, A.; Esposito, M.; Carboni, I.; Schipani, C.; Chimenti, S. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J. Dermatolog. Treat., 2007, 18(2), 84-87.
[http://dx.doi.org/10.1080/09546630601123835] [PMID: 17520464]
[4]
Mehnert, W.; Mäder, K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev., 2012, 64, 83-101.
[http://dx.doi.org/10.1016/j.addr.2012.09.021] [PMID: 11311991]
[5]
Müller, R.H.; Petersen, R.D.; Hommoss, A.; Pardeike, J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev., 2007, 59(6), 522-530.
[http://dx.doi.org/10.1016/j.addr.2007.04.012] [PMID: 17602783]
[6]
Proksch, E.; Fölster-Holst, R.; Jensen, J-M. Skin barrier function, epidermal proliferation and differentiation in eczema. J. Dermatol. Sci., 2006, 43(3), 159-169.
[http://dx.doi.org/10.1016/j.jdermsci.2006.06.003] [PMID: 16887338]
[7]
Simpson, E.L. Atopic dermatitis: A review of topical treatment options. Curr. Med. Res. Opin., 2010, 26(3), 633-640.
[http://dx.doi.org/10.1185/03007990903512156] [PMID: 20070141]
[8]
Mathes, C.; Melero, A.; Conrad, P.; Vogt, T.; Rigo, L.; Selzer, D.; Prado, W.A.; De Rossi, C.; Garrigues, T.M.; Hansen, S.; Guterres, S.S.; Pohlmann, A.R.; Beck, R.C.R.; Lehr, C.M.; Schaefer, U.F. Nanocarriers for optimizing the balance between interfollicular permeation and follicular uptake of topically applied clobetasol to minimize adverse effects. J. Control. Release, 2016, 223, 207-214.
[http://dx.doi.org/10.1016/j.jconrel.2015.12.010] [PMID: 26686081]
[9]
Li, B.; Ge, Z-Q. Nanostructured lipid carriers improve skin permeation and chemical stability of idebenone. AAPS PharmSciTech, 2012, 13(1), 276-283.
[http://dx.doi.org/10.1208/s12249-011-9746-3] [PMID: 22234598]
[10]
Khurana, S.; Bedi, P.; Jain, N. Development of nanostructured lipid carriers for controlled delivery of mefenamic acid. Int. J. Biomed. Nanosci. Nanotechnol., 2012, 2(3-4), 232-250.
[http://dx.doi.org/10.1504/IJBNN.2012.051218]
[11]
Mathes, C.; Melero, A.; Conrad, P.; Vogt, T.; Rigo, L.; Selzer, D.; Prado, W.A.; De Rossi, C.; Garrigues, T.M.; Hansen, S.; Guterres, S.S.; Pohlmann, A.R.; Beck, R.C.R.; Lehr, C.M.; Schaefer, U.F. Nanocarriers for optimizing the balance between interfollicular permeation and follicular uptake of topically applied clobetasol to minimize adverse effects. J. Control. Release, 2016, 223, 207-214.
[http://dx.doi.org/10.1016/j.jconrel.2015.12.010] [PMID: 26686081]
[12]
Silva, L.A.D.; Andrade, L.M.; de Sá, F.A.; Marreto, R.N.; Lima, E.M.; Gratieri, T.; Taveira, S.F. Clobetasol-loaded nanostructured lipid carriers for epidermal targeting. J. Pharm. Pharmacol., 2016, 68(6), 742-750.
[http://dx.doi.org/10.1111/jphp.12543] [PMID: 27061573]
[13]
Aljuffali, I.A.; Sung, C.T.; Shen, F.M.; Huang, C.T.; Fang, J.Y. Squarticles as a lipid nanocarrier for delivering diphencyprone and minoxidil to hair follicles and human dermal papilla cells. AAPS J., 2014, 16(1), 140-150.
[http://dx.doi.org/10.1208/s12248-013-9550-y] [PMID: 24307611]
[14]
Ekambaram, P.; Abdul, H.S. Formulation and evaluation of solid lipid nanoparticles of ramipril. J. Young Pharm., 2011, 3(3), 216-220.
[http://dx.doi.org/10.4103/0975-1483.83765] [PMID: 21897661]
[15]
Vernon, B.; Martinez, A. Gel strength and solution viscosity of temperature-sensitive, in-situ-gelling polymers for endovascular embolization. J. Biomater. Sci. Polym. Ed., 2005, 16(9), 1153-1166.
[http://dx.doi.org/10.1163/1568562054798536] [PMID: 16231605]
[16]
de Andrade, D.F.; Fontana, M.C.; Pohlmann, A.R.; Guterres, S.S.; Carlos, R.; Beck, R. Nanoencapsulation of clobetasol propionate decreases its penetration to skin layers without changing its relative skin distribution. J. Nanosci. Nanotechnol., 2015, 15(1), 875-879.
[http://dx.doi.org/10.1166/jnn.2015.9183] [PMID: 26328452]
[17]
Nakaguma, H.; Kambara, T.; Yamamoto, T. Rat ultraviolet ray B photodermatitis: An experimental model of psoriasis vulgaris. Int. J. Exp. Pathol., 1995, 76(1), 65-73.
[PMID: 7734340]
[18]
Patel, N.; Patel, P.; Meshram, D. A development and validation of RP-HPLC method for simultaneous estimation of Nadifloxacin and Clobetasol Propionate in its pharmaceutical dosage form; , 2016, Vol. 6, pp. 289-304.
[19]
Agarwal, R.; Katare, O.P.; Vyas, S.P. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int. J. Pharm., 2001, 228(1-2), 43-52.
[http://dx.doi.org/10.1016/S0378-5173(01)00810-9] [PMID: 11576767]
[20]
Hartman, R.I.; Kimball, A.B. Clinical presentation of psoriasis and psoriatic arthritis. Handbook of Psoriasis and Psoriatic Arthritis; Springer, 2016, pp. 17-26.
[http://dx.doi.org/10.1007/978-3-319-18227-8_3]
[21]
Campbell, C.S.; Contreras-Rojas, L.R.; Delgado-Charro, M.B.; Guy, R.H. Objective assessment of nanoparticle disposition in mammalian skin after topical exposure. J. Control. Release, 2012, 162(1), 201-207.
[http://dx.doi.org/10.1016/j.jconrel.2012.06.024] [PMID: 22732479]
[22]
Gordon, M.L. The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses. Clin. Ther., 1998, 20(1), 26-39.
[http://dx.doi.org/10.1016/S0149-2918(98)80032-5] [PMID: 9522102]
[23]
Feldman, S.R. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr. Ther. Res. Clin. Exp., 2005, 66(3), 154-171.
[http://dx.doi.org/10.1016/j.curtheres.2005.06.010] [PMID: 24672120]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 3
Year: 2021
Published on: 28 June, 2020
Page: [399 - 411]
Pages: 13
DOI: 10.2174/1874467213666200628135552
Price: $65

Article Metrics

PDF: 150
HTML: 1